5 results
To assess safety, tolerability, and PK of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and Budigalimab in subjects with R/M HNSCC.
Induction PeriodPrimary:Demonstrate the efficacy of RPC1063 versus placebo on induction of clinical remission.Secondary:* Demonstrate the efficacy of RPC1063 versus placebo on induction of clinical response* Demonstrate the efficacy of RPC1063…
Primary Objective:- Demonstrate the efficacy of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic responseSecondary Objectives:- Demonstrate the efficacy of ozanimod compared to placebo on maintenance of clinical…
Primary objective:- Demonstrate the efficacy of ozanimod compared to placebo on the induction of clinical remissionSecondary objectives:- Demonstrate the efficacy of ozanimod compared to placebo on induction of clinical response, clinical remission…
The objective of this study is to demonstrate the long-term safety and explore tong-term efficacy of ozanimod for the treatment of subjects with moderately to severely active CD.